Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Revenue growth | — | — | — | -32.1% | -33.3% | 71.4% | 1.0% |
| Operating income | -$35.5M | -$60.4M | -$82.1M | -$130M | -$139M | -$120M | -$115M |
| Operating margin | — | — | -179.4% | -416.6% | -669.8% | -336.1% | -320.5% |
| Net income | -$34.1M | -$66.3M | -$83.9M | -$128M | -$132M | -$105M | -$105M |
| Net margin | — | — | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| EPS (diluted) | -$31.03 | -$5.83 | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $55.6M | -$67.2M | -$87.0M | -$106M | -$107M | -$65.2M | -$98.7M |
| Capital expenditures | $1.35M | $650K | $1.28M | $5.50M | $1.71M | $180K | $607K |
| Free cash flow | $54.3M | -$67.9M | -$88.2M | -$111M | -$109M | -$65.3M | -$99.3M |
| Share buybacks | $30.0K | $100K | — | $0.00 | $110K | $194K | $193K |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $90.5M | $182M | $76.1M | $29.8M | $127M | $55.5M | $74.6M |
| Total assets | $118M | $400M | $507M | $431M | $376M | $350M | $359M |
| Total liabilities | $119M | $119M | $117M | $142M | $130M | $134M | $102M |
| Long-term debt | — | $10.1M | $10.8M | $9.20M | $0.00 | — | — |
| Shareholders' equity | -$112M | $281M | $390M | $289M | $246M | $216M | $257M |
| Retained earnings | -$117M | -$184M | -$268M | -$396M | -$528M | -$634M | -$739M |
| Shares (wtd avg diluted) | 1.43M | 43.1M | 46.0M | 48.9M | 49.6M | 69.4M | 82.9M |
Every figure is extracted from C4 Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.